Lupeol

Pharmacology & Research

Lupeol is a pentacyclic triterpene of the lupane class found across a very wide range of edible plants — mango, dandelion, nettle, muira puama and many medicinal herbs — usually as a minor part of the triterpene fraction. It is one of the more heavily studied plant triterpenes, and its literature has a clear shape: a large, mechanistically coherent preclinical anticancer and anti-inflammatory body, and essentially no human trials. The single most important qualifier is pharmacokinetic — lupeol is extremely lipophilic (log P ≈ 7.7) with very low aqueous solubility and poor oral bioavailability ^{11,12Reference 112019AnimalAbsorption and distribution of lupeol in CD-1 mice evaluated by UPLC-APCI(+)-MS/MSView study →Reference 122024In-depth analysis of lupeol: delving into the diverse pharmacological profileView study →}, so the striking in-vitro potencies are not obviously reachable from oral intake. Its mechanism is genuinely multi-target: modulation of Wnt/β-catenin, NF-κB, PI3K/Akt and STAT3 signalling ^{3,4,7Reference 3Saleem M et al. · 2004AnimalLupeol modulates NF-κB and PI3K/Akt pathways and inhibits skin cancer in CD-1 miceView study →Reference 4Saleem M et al. · 2009Lupeol inhibits proliferation of human prostate cancer cells by targeting β-catenin signallingView study →Reference 72014Negative regulation of the STAT-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cellsView study →}.

1. Anticancer

Lupeol’s marquee application. Topical lupeol suppressed tumour promotion in mouse skin carcinogenesis via NF-κB and PI3K/Akt ^{3Reference 3Saleem M et al. · 2004AnimalLupeol modulates NF-κB and PI3K/Akt pathways and inhibits skin cancer in CD-1 miceView study →}; it inhibited human prostate cancer proliferation by targeting β-catenin/GSK3β/MMP-2 signalling ^{4Reference 4Saleem M et al. · 2009Lupeol inhibits proliferation of human prostate cancer cells by targeting β-catenin signallingView study →}; selectively killed melanoma cells with constitutive Wnt/β-catenin activation ^{5Reference 5Tarapore RS et al. · 2010Specific targeting of Wnt/β-catenin signalling in human melanoma cells by the dietary triterpene lupeolView study →}; and blocked STAT3 (via SHP-2) in hepatocellular carcinoma cells ^{7Reference 72014Negative regulation of the STAT-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cellsView study →}. The breadth and multi-target mechanism make it a repeated review headliner ^{1,2Reference 1Saleem M · 2009Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpeneView study →Reference 2Siddique HR · 2011ReviewBeneficial health effects of lupeol triterpene: a review of preclinical studiesView study →}.

Gap: essentially all data are cell-line and mouse, with no controlled human efficacy data, and poor oral bioavailability makes dietary/oral relevance unproven ^{11,12Reference 112019AnimalAbsorption and distribution of lupeol in CD-1 mice evaluated by UPLC-APCI(+)-MS/MSView study →Reference 122024In-depth analysis of lupeol: delving into the diverse pharmacological profileView study →}.

2. Anti-inflammatory / arthritis

Lupeol and lupeol linoleate reduced paw swelling in rat adjuvant-induced arthritis (by 39% and 58% versus indomethacin’s 35%), without antinociceptive, antipyretic or ulcerogenic effects ^{8Reference 8Geetha T · 2001AnimalAnti-inflammatory activity of lupeol and lupeol linoleate in ratsView study →} — a clean anti-inflammatory profile anchored to NF-κB suppression ^{1Reference 1Saleem M · 2009Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpeneView study →}.

Gap: injected/high-dose animal dosing, with no human anti-inflammatory trials and oral relevance limited by absorption ^{8Reference 8Geetha T · 2001AnimalAnti-inflammatory activity of lupeol and lupeol linoleate in ratsView study →}.

3. Skin / topical anti-inflammatory

Topical lupeol inhibited TPA-induced skin edema and hyperplasia in mice ^{3Reference 3Saleem M et al. · 2004AnimalLupeol modulates NF-κB and PI3K/Akt pathways and inhibits skin cancer in CD-1 miceView study →} and alleviated atopic-dermatitis-like inflammation in a DNCB/Dermatophagoides farinae mouse model ^{9Reference 92023AnimalLupeol alleviates atopic-dermatitis-like skin inflammation in DNCB/Dermatophagoides farinae-induced miceView study →}. Because the topical route sidesteps the oral-bioavailability problem, skin is the most plausible near-term application.

Gap: animal-only, with no human topical trials and no established skin-penetration formulation for such a lipophilic molecule ^{3,9Reference 3Saleem M et al. · 2004AnimalLupeol modulates NF-κB and PI3K/Akt pathways and inhibits skin cancer in CD-1 miceView study →Reference 92023AnimalLupeol alleviates atopic-dermatitis-like skin inflammation in DNCB/Dermatophagoides farinae-induced miceView study →}.

4. Hepatoprotective

Lupeol is repeatedly reported to protect against chemically-induced liver injury (e.g. cadmium, CCl₄-type) by restoring antioxidant defences in rats, as aggregated in preclinical reviews ^{1,2Reference 1Saleem M · 2009Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpeneView study →Reference 2Siddique HR · 2011ReviewBeneficial health effects of lupeol triterpene: a review of preclinical studiesView study →}.

Gap: model-dependent and review-level, with no human data ^{1,2Reference 1Saleem M · 2009Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpeneView study →Reference 2Siddique HR · 2011ReviewBeneficial health effects of lupeol triterpene: a review of preclinical studiesView study →}.

5. Metabolic / antidiabetic

Lupeol (with iso-orientin) lowered blood glucose and oxidative-stress markers in a rat model, supported by docking and enzyme-inhibition data ^{10Reference 102019AnimalIn-silico and in-vitro studies of lupeol and iso-orientin as potential antidiabetic agents in a rat modelView study →}.

Gap: small, mechanism-forward and often confounded by co-administered compounds, with no standalone human evidence ^{10Reference 102019AnimalIn-silico and in-vitro studies of lupeol and iso-orientin as potential antidiabetic agents in a rat modelView study →}.

6. Antimicrobial

Lupeol is among pentacyclic triterpenoids showing antibacterial and synergistic activity in vitro ^{13Reference 132016Antibacterial and synergistic activity of pentacyclic triterpenoids isolated from Alstonia scholarisView study →}.

Gap: modest potency, in-vitro only and frequently as part of mixtures — the least-developed application ^{13Reference 132016Antibacterial and synergistic activity of pentacyclic triterpenoids isolated from Alstonia scholarisView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Wnt / β-catenin (↓ nuclear β-catenin, GSK3β/MMP-2)	↓ proliferation, invasion, metastasis signalling	prostate cancer, melanoma
NF-κB (↓ activation)	anti-inflammatory; anti-tumour-promoting	skin carcinogenesis, arthritis
PI3K / Akt (↓ signalling)	pro-apoptotic; blocks survival signalling	skin cancer
STAT3 (↓ Tyr705 via ↑ SHP-2)	growth inhibition, apoptosis	hepatocellular carcinoma
cFLIP / MYC (↓; in-silico + in-vitro)	restores apoptosis sensitivity, chemosensitisation	therapy-resistant prostate cancer

Pharmacokinetics

Load-bearing and the central limitation. Lupeol is highly lipophilic (octanol/water log P ≈ 7.67) with extremely low aqueous solubility, which severely limits its dissolution in GI fluids and hence oral absorption ^{12Reference 122024In-depth analysis of lupeol: delving into the diverse pharmacological profileView study →}. In-vivo work confirms poor, erratic systemic exposure — absorption and tissue distribution in mice, characterised by mass spectrometry, document the low-exposure profile ^{11Reference 112019AnimalAbsorption and distribution of lupeol in CD-1 mice evaluated by UPLC-APCI(+)-MS/MSView study →} — which is precisely why the field has pivoted to nanostructured lipid carriers, solid lipid nanoparticles and other delivery engineering to raise bioavailability ^{12Reference 122024In-depth analysis of lupeol: delving into the diverse pharmacological profileView study →}. The practical implication: the impressive in-vitro concentrations are not obviously achievable from oral intake of unformulated lupeol, so preclinical potency should not be read as oral human efficacy.

Clinical trials

There are no completed randomised controlled human efficacy trials of isolated lupeol for any indication. The entire evidence base is in-vitro and animal, aggregated in preclinical reviews ^{1,2,12Reference 1Saleem M · 2009Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpeneView study →Reference 2Siddique HR · 2011ReviewBeneficial health effects of lupeol triterpene: a review of preclinical studiesView study →Reference 122024In-depth analysis of lupeol: delving into the diverse pharmacological profileView study →}. Any human-facing claim should be labelled preclinical/investigational only.

Last checked: July 2026.

Toxicity & Safety

Lupeol’s low observed toxicity is a genuine point in its favour: it is a normal constituent of many edible fruits and vegetables, is repeatedly reported as well tolerated at high oral doses in rodents, and appears not to harm normal cells at effective doses in the preclinical literature ^{1,2Reference 1Saleem M · 2009Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpeneView study →Reference 2Siddique HR · 2011ReviewBeneficial health effects of lupeol triterpene: a review of preclinical studiesView study →} — the rat anti-arthritic work, for instance, produced its effect without ulcerogenic, antipyretic or antinociceptive liability ^{8Reference 8Geetha T · 2001AnimalAnti-inflammatory activity of lupeol and lupeol linoleate in ratsView study →}. That said, formal acute/chronic toxicology and a clean LD50 for isolated lupeol are not well established, so the “low toxicity” verdict rests on aggregate preclinical observation plus dietary ubiquity rather than regulatory-grade studies, and the isolated concentrated-supplement profile in humans is uncharacterised. There is no human drug-interaction data; because lupeol modulates NF-κB, PI3K/Akt, STAT3 and β-catenin and can chemosensitise cancer cells ^{6Reference 62022Role of lupeol in chemosensitising therapy-resistant prostate cancer cells by targeting MYC, β-catenin and c-FLIP: in-silico and in-vitro studiesView study →}, theoretical additive or interfering effects with anti-inflammatory or oncologic drugs cannot be excluded.

Dosage

There is no human dose for lupeol, and the following are research doses, not recommendations. Rodent studies used roughly 1–2 mg/mouse topically for skin models ^{3Reference 3Saleem M et al. · 2004AnimalLupeol modulates NF-κB and PI3K/Akt pathways and inhibits skin cancer in CD-1 miceView study →} and oral or parenteral doses of tens of mg/kg for systemic anti-inflammatory and anticancer models ^{8,2Reference 8Geetha T · 2001AnimalAnti-inflammatory activity of lupeol and lupeol linoleate in ratsView study →Reference 2Siddique HR · 2011ReviewBeneficial health effects of lupeol triterpene: a review of preclinical studiesView study →}. These do not translate to a human supplement dose, and the poor oral bioavailability means an unformulated oral dose has unpredictable exposure.

References